Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

GLOMERULAR DISEASE

MENTOR heralds a new era of therapy for membranous nephropathy

Nature Reviews Nephrology volume 15, pages 664–666 (2019)Cite this article

Subjects

The MENTOR trial reported that rituximab is superior to ciclosporin for remission of nephrotic syndrome in patients with membranous nephropathy. Rituximab is better tolerated than other treatments but, as up to 40% of patients did not respond to rituximab, alternative immunosuppressive therapies may still be required for a substantial minority of patients.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Fig. 1: Suggested initial therapy for the treatment of membranous nephropathy.

References

  1. Fervenza, F. C. et al. Rituximab or cyclosporine in the treatment of membranous nephropathy. N. Engl. J. Med. 381, 36–46 (2019).

    Article  CAS  Google Scholar 

  2. Cattran, D. C. et al. Cyclosporine in patients with steroid-resistant membranous nephropathy: a randomized trial. Kidney Int. 59, 1484–1490 (2001).

    Article  CAS  Google Scholar 

  3. Howman, A. et al. Immunosuppression for progressive membranous nephropathy: a UK randomised controlled trial. Lancet 381, 744–751 (2013).

    Article  CAS  Google Scholar 

  4. van den Brand, J. et al. Safety of rituximab compared with steroids and cyclophosphamide for idiopathic membranous nephropathy. J. Am. Soc. Nephrol. 28, 2729–2737 (2017).

    Article  Google Scholar 

  5. Praga, M. et al. Tacrolimus monotherapy in membranous nephropathy: a randomized controlled trial. Kidney Int. 71, 924–930 (2007).

    Article  CAS  Google Scholar 

  6. Hamilton, P. et al. Rituximab versus the modified Ponticelli regimen in the treatment of primary membranous nephropathy: a health economic model. Nephrol. Dial. Transplant. 33, 2145–2155 (2018).

    Article  CAS  Google Scholar 

  7. van de Logt, A. E. et al. Immunological remission in PLA2R-antibody-associated membranous nephropathy: cyclophosphamide versus rituximab. Kidney Int. 93, 1016–1017 (2018).

    Article  Google Scholar 

  8. Cortazar, F. B. et al. Combination therapy with rituximab, low-dose cyclophosphamide, and prednisone for idiopathic membranous nephropathy: a case series. BMC Nephrol. 18, 44 (2017).

    Article  Google Scholar 

  9. Barrett, C. et al. Effect of belimumab on proteinuria and anti-phospholipase A2 receptor autoantibody in primary membranous nephropathy. Nephrol. Dial. Transplant. https://doi.org/10.1093/ndt/gfz086 (2019).

    Article  PubMed  Google Scholar 

  10. Seitz-Polski, B. et al. Phospholipase A2 receptor 1 epitope spreading at baseline predicts reduced likelihood of remission of membranous nephropathy. J. Am. Soc. Nephrol. 29, 401–408 (2018).

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Renal and Transplant Centre, Imperial College Healthcare NHS Trust, London, UK

    Aikaterini Nikolopoulou & Megan Griffith

Authors
  1. Aikaterini Nikolopoulou
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Megan Griffith
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Megan Griffith.

Ethics declarations

Competing interests

The authors declare no competing interests.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Nikolopoulou, A., Griffith, M. MENTOR heralds a new era of therapy for membranous nephropathy. Nat Rev Nephrol 15, 664–666 (2019). https://doi.org/10.1038/s41581-019-0200-1

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41581-019-0200-1

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing